Arterial Intra-Occular Hypertension
The use of FECO (Full Extract Cannabis Oil) for Arterial Intra-Ocular Hypertension (elevated pressure within the eye, often a precursor to glaucoma) is a subject of significant clinical refinement. While the ability of cannabinoids to lower intra-ocular pressure (IOP) has been known since the 1970s, FECO is specifically valued in 2026 for its "Multi-Target" approach to eye health.
1. Direct Reduction of Intra-Ocular Pressure (IOP)
The primary benefit of FECO is its ability to reduce the fluid pressure that damages the optic nerve.
Dual-Action Outflow: Research updated in late 2025 indicates that THC and CBD work together to both decrease aqueous humor production (the fluid entering the eye) and increase aqueous outflow through the trabecular meshwork.
Average Efficacy: Clinical data from 2026 shows that high-potency FECO can reduce IOP by 25% to 30%. This is comparable to the efficacy of some standard prostaglandin eye drops, but without the common side effect of "red-eye" or eyelash thickening.
2. Neuroprotection of the Retinal Ganglion Cells (RGCs)
A major 2026 breakthrough is the understanding that high-pressure damage isn't just mechanical; it’s metabolic.
Glutamate Regulation: High ocular pressure causes a toxic buildup of glutamate, which "excites" and kills retinal nerves. FECO acts as a potent antioxidant and neuroprotectant, neutralizing free radicals and preventing the death of Retinal Ganglion Cells even when pressure spikes occur.
CB1/CB2 Synergy: The full spectrum of cannabinoids in FECO ensures that receptors in the retina, ciliary body, and Schlemm’s canal are all engaged, providing a "shield" for the optic nerve head.
3. Vasodilation and Ocular Blood Flow
Many patients with ocular hypertension also suffer from restricted blood flow to the back of the eye.
Improving Micro-Circulation: FECO is a natural vasodilator. By relaxing the smooth muscles of the ocular blood vessels, it improves the delivery of oxygen and nutrients to the optic nerve.
The Blood Pressure Factor: In 2026, clinicians monitor the "Perfusion Pressure." Because FECO can also lower systemic blood pressure, doctors ensure the dose is balanced so that the blood pressure in the eye remains high enough to keep the nerve healthy while the internal fluid pressure stays low.
FECO vs. Standard Ocular Medications (2026)
| Feature | Beta-Blocker Drops (e.g., Timolol) | FECO (Full Extract) |
|---|---|---|
| IOP Lowering | Reliable; 24-hour control. | High; but short duration (3–4 hrs). |
| Neuroprotection | Minimal. | Excellent; protects nerve cells. |
| Local Side Effects | Stinging, dry eyes, blurry vision. | Minimal (if taken orally/sublingually). |
| Systemic Impact | Can lower heart rate. | Euphoria, relaxation, lower BP. |
4. 2026 "Ocular Maintenance" Protocol
Because the pressure-lowering effects of FECO are relatively short-lived (lasting about 3–4 hours), 2026 protocols emphasize frequency over volume:
The "Micro-Squeeze" Method: Rather than one large dose, patients use a syringe to apply a "pinhead" amount of FECO under the tongue every 4 hours.
CBN Integration: In 2026, CBN (Cannabinol) is often added to the FECO blend for eye health, as it has shown superior neuroprotective effects compared to THC or CBD alone in recent 2025 clinical trials.
Nighttime "Anchor": A larger dose (50mg capsule) is taken at bedtime to prevent the early morning pressure spikes that commonly occur between 3:00 AM and 6:00 AM.
2026 Clinical Warning
The CBD Paradox: Some 2024 studies suggested that pure CBD isolates could actually increase intra-ocular pressure in certain individuals. However, Full Extract (FECO) preserves the THC and terpenes that counteract this effect. Patients with high eye pressure should avoid CBD isolates and always use a Full-Spectrum product.
